Sageworth Trust Co Trims Stock Holdings in Abbott Laboratories $ABT

Sageworth Trust Co lowered its holdings in shares of Abbott Laboratories (NYSE:ABT) by 64.1% in the fourth quarter, Holdings Channel.com reports. The fund owned 20,358 shares of the healthcare product maker’s stock after selling 36,353 shares during the quarter. Sageworth Trust Co’s holdings in Abbott Laboratories were worth $2,551,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of ABT. Harbor Capital Advisors Inc. purchased a new position in Abbott Laboratories in the 4th quarter worth about $27,000. Cloud Capital Management LLC bought a new position in Abbott Laboratories in the 3rd quarter worth about $29,000. Guerra Advisors Inc purchased a new position in shares of Abbott Laboratories during the third quarter worth approximately $31,000. Bridge Generations Wealth Management LLC bought a new stake in shares of Abbott Laboratories during the third quarter valued at approximately $33,000. Finally, Copia Wealth Management purchased a new position in Abbott Laboratories during the 3rd quarter worth $38,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Down 1.1%

NYSE:ABT opened at $86.25 on Thursday. The company’s 50-day simple moving average is $103.25 and its 200-day simple moving average is $115.39. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. Abbott Laboratories has a fifty-two week low of $86.15 and a fifty-two week high of $139.06. The stock has a market capitalization of $150.23 billion, a P/E ratio of 24.16, a P/E/G ratio of 1.45 and a beta of 0.65.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The company had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. Abbott Laboratories’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.9%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s payout ratio is 70.59%.

Insider Activity at Abbott Laboratories

In related news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the transaction, the executive vice president directly owned 146,377 shares of the company’s stock, valued at $16,918,253.66. This represents a 0.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Daniel J. Starks purchased 10,000 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were acquired at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the purchase, the director directly owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold a total of 3,055 shares of company stock worth $353,097 over the last ninety days. Corporate insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on ABT shares. Daiwa Securities Group lowered Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target on the stock. in a research note on Wednesday, April 22nd. UBS Group dropped their target price on shares of Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating on the stock in a report on Monday, April 20th. Wells Fargo & Company reduced their price target on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Barclays lowered their price target on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research report on Monday, April 20th. Finally, Jefferies Financial Group cut their price objective on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average target price of $119.43.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.